Patents by Inventor Eggehard Holler
Eggehard Holler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200206304Abstract: Mini nanodrugs that include a polymalic-based molecular scaffold with one or more peptides capable of crossing the blood-brain barrier, one or more plaque-binding peptides and one or more therapeutic agents attached to the scaffold are provided. Methods of treating brain diseases or abnormal conditions, and imaging of the same in a subject by administering the mini nanodrugs are described. Methods for reducing formation of amyloid plaques in the brain of a subject are disclosed.Type: ApplicationFiled: March 11, 2020Publication date: July 2, 2020Applicant: Cedars-Sinai Medical CenterInventors: Eggehard Holler, Julia Y. Ljubimova, Keith L. Black
-
Publication number: 20200155593Abstract: Nanobiopolymeric conjugates based on biodegradable, non-toxic and non-immunogenic poly (?-L-malic acid) PMLA covalently linked to molecular modules that include morpholino antisense oligonucleotides (AONa), an siRNA or an antibody specific for an oncogenic protein in a cancer cell, and an antibody specific for a transferrin receptor protein, are provided. Methods for treating a cancer in subject with nanobiopolymeric conjugates are described.Type: ApplicationFiled: January 27, 2020Publication date: May 21, 2020Inventors: Satoshi Inoue, Hui Ding, Eggehard Holler, Keith L. Black, Julia Y. Ljubimova
-
Patent number: 10583151Abstract: Nanobiopolymeric conjugates based on biodegradable, non-toxic and non-immunogenic poly (?-L-malic acid) PMLA covalently linked to molecular modules that include morpholino antisense oligonucleotides (AONa), an siRNA or an antibody specific for an oncogenic protein in a cancer cell, and an antibody specific for a transferrin receptor protein, are provided. Methods for treating a cancer in subject with nanobiopolymeric conjugates are described.Type: GrantFiled: March 2, 2017Date of Patent: March 10, 2020Assignee: Cedars-Sinai Medical CenterInventors: Satoshi Inoue, Hui Ding, Eggehard Holler, Keith L. Black, Julia Y. Ljubimova
-
Publication number: 20190321494Abstract: Nanoconjugates that include a polymalic-based molecular scaffold with one or more imaging moiety and one or more targeting modules attached to the scaffold are provided. Methods of targeting a diseased cell or a diseased tissue in a subject by administering the nanoconjugate are described. Methods of synthesizing the nanoconjugate are also provided.Type: ApplicationFiled: June 7, 2019Publication date: October 24, 2019Applicant: Cedars-Sinai Medical CenterInventors: Keith L. Black, Julia Ljubimova, Alexander Ljubimov, Eggehard Holler
-
Patent number: 10383958Abstract: Nanoconjugates that include a polymalic-based molecular scaffold with one or more imaging moiety and one or more targeting modules attached to the scaffold are provided. Methods of targeting a diseased cell or a diseased tissue in a subject by administering the nanoconjugate are described. Methods of synthesizing the nanoconjugate are also provided.Type: GrantFiled: April 6, 2012Date of Patent: August 20, 2019Assignee: CEDARS-SINAI MEDICAL CENTERInventors: Keith L. Black, Julia Ljubimova, Alexander Ljubimov, Eggehard Holler
-
Publication number: 20190076555Abstract: Imaging nanoagents including a polymalic acid-based molecular scaffold, a chlorotoxin peptide or a variant thereof, and at least one fluorescent moiety are provided. Methods for detecting, treating and removing a cancer in a subject by administering the imaging nanoagent are described.Type: ApplicationFiled: September 12, 2018Publication date: March 14, 2019Applicant: Cedars-Sinai Medical CenterInventors: Rameshwar Patil, Eggehard Holler, Julia Y. Ljubimova, Adam Mamelak, Keith L. Black
-
Publication number: 20190060479Abstract: Nanoimmunoconjugates including a polymalic acid-based molecular scaffold, targeting ligands, anti-tumor immune response stimulators and anti-cancer agents are provided. Methods for treating cancer in a subject by administering the nanoimmunoconjugates that provide both systemic and local immune responses and synergistic anticancer effect are described.Type: ApplicationFiled: March 3, 2017Publication date: February 28, 2019Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Julia Y. LJUBIMOVA, Keith L. BLACK, Eggehard HOLLER, Alexander LJUBIMOV, Hui DING
-
Publication number: 20170340659Abstract: Nanobiopolymeric conjugates based on biodegradable, non-toxic and non-immunogenic poly (?-L-malic acid) PMLA covalently linked to molecular modules that include morpholino antisense oligonucleotides (AONa), an siRNA or an antibody specific for an oncogenic protein in a cancer cell, and an antibody specific for a transferrin receptor protein, are provided. Methods for treating a cancer in subject with nanobiopolymeric conjugates are described.Type: ApplicationFiled: March 2, 2017Publication date: November 30, 2017Inventors: Satoshi Inoue, Hui Ding, Eggehard Holler, Keith L. Black, Julia Y. Ljubimova
-
Patent number: 9827325Abstract: The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety.Type: GrantFiled: March 6, 2017Date of Patent: November 28, 2017Assignee: CEDARS-SINAI MEDICAL CENTERInventors: Rameshwar Patil, Eggehard Holler, Keith L. Black, Julia Y. Ljubimova
-
Publication number: 20170274085Abstract: The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety.Type: ApplicationFiled: March 6, 2017Publication date: September 28, 2017Inventors: Rameshwar Patil, Eggehard Holler, Keith L. Black, Julia Y. Ljubimova
-
Patent number: 9629919Abstract: The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety.Type: GrantFiled: February 26, 2016Date of Patent: April 25, 2017Assignee: CEDARS-SINAI MEDICAL CENTERInventors: Rameshwar Patil, Eggehard Holler, Keith L. Black, Julia Y. Ljubimova
-
Patent number: 9623041Abstract: Nanobiopolymeric conjugates based on biodegradable, non-toxic and non-immunogenic poly (?-L-malic acid) PMLA covalently linked to molecular modules that include morpholino antisense oligonucleotides (AONa), an siRNA or an antibody specific for an oncogenic protein in a cancer cell, and an antibody specific for a transferrin receptor protein, are provided. Methods for treating a cancer in subject with nanobiopolymeric conjugates are described.Type: GrantFiled: June 28, 2013Date of Patent: April 18, 2017Assignee: CEDARS-SINAI MEDICAL CENTERInventors: Satoshi Inoue, Hui Ding, Eggehard Holler, Keith L. Black, Julia Y. Ljubimova
-
Publication number: 20160175450Abstract: The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety.Type: ApplicationFiled: February 26, 2016Publication date: June 23, 2016Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Rameshwar Patil, Eggehard Holler, Keith L. Black, Julia Y. Ljubimova
-
Patent number: 9320807Abstract: The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety.Type: GrantFiled: February 12, 2014Date of Patent: April 26, 2016Assignee: CEDARS-SINAI MEDICAL CENTERInventors: Rameshwar Patil, Eggehard Holler, Keith L. Black, Julia Y. Ljubimova
-
Patent number: 8911717Abstract: A drug delivery system for delivering a drug payload to a specific tissue or cell type is disclosed. The system includes a polymalic acid molecular scaffold which can be used for attaching a plurality of molecular modules. Molecular modules include targeting antibodies for promoting cellular uptake by a target cell, and pro-drugs for altering cellular metabolism, for example, a pro-drug that alters expression of protein kinase CK2.Type: GrantFiled: September 19, 2013Date of Patent: December 16, 2014Assignees: Cedars-Sinai Medical Center, Arrogene Nanotechnology, Inc.Inventors: Julia Y. Ljubimova, Keith L. Black, Eggehard Holler
-
Patent number: 8795648Abstract: The invention relates to the use of Polycefin-LLL nanoconjugate as a means of cytoplasmic delivery of drugs. In one embodiment, the present invention provides a drug delivery molecule, comprising a polymerized carboxylic acid molecular scaffold covalently linked to L-leucylleucylleucine. In another embodiment, the Polycefin-LLL includes drug antisense morpholino oligos, targeting antibodies, and a pH-sensitive endosome escape unit. In addition, the drug could be siRNA, microRNA, and aptamer.Type: GrantFiled: October 8, 2012Date of Patent: August 5, 2014Assignee: Cedars-Sinai Medical CenterInventors: Hui Ding, Julia Y. Ljubimova, Eggehard Holler, Keith L. Black
-
Patent number: 8785371Abstract: The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety.Type: GrantFiled: December 10, 2010Date of Patent: July 22, 2014Assignee: Cedars-Sinai Medical CenterInventors: Rameshwar Patil, Eggehard Holler, Keith L. Black, Julia Y. Ljubimova
-
Publication number: 20140193398Abstract: Nanobiopolymeric conjugates based on biodegradable, non-toxic and non-immunogenic poly (?-L-malic acid) PMLA covalently linked to molecular modules that include morpholino antisense oligonucleotides (AONa), an siRNA or an antibody specific for an oncogenic protein in a cancer cell, and an antibody specific for a transferrin receptor protein, are provided. Methods for treating a cancer in subject with nanobiopolymeric conjugates are described.Type: ApplicationFiled: June 28, 2013Publication date: July 10, 2014Inventors: Satoshi Inoue, Hui Ding, Eggehard Holler, Keith L. Black, Julia Y. Ljubimova
-
Publication number: 20140161762Abstract: The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety.Type: ApplicationFiled: February 12, 2014Publication date: June 12, 2014Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Rameshwar Patil, Eggehard Holler, Keith L. Black, Julia Y. Ljubimova
-
Publication number: 20140039125Abstract: A drug delivery system for delivering a drug payload to a specific tissue or cell type is disclosed. The system includes a polymalic acid molecular scaffold which can be used for attaching a plurality of molecular modules. Molecular modules include targeting antibodies for promoting cellular uptake by a target cell, and pro-drugs for altering cellular metabolism, for example, a pro-drug that alters expression of protein kinase CK2.Type: ApplicationFiled: September 19, 2013Publication date: February 6, 2014Applicants: Arrogene Nanotechnology, Inc., Cedars-Sinai Medical CenterInventors: Julia Y. Ljubimova, Keith L. Black, Eggehard Holler